Summary
This study is testing a new drug called (BBO-11818) for people with advanced cancers that have a change (mutation) in a gene called KRAS.
The aims of the study are to:
- Check how safe the drug is
- Find out what side effects it may cause
- See how the body handles the drug
- Look for early signs that it may help shrink or control cancer
Who can take part?
You may be able to join this study if you have an advanced solid cancer, such as lung, bowel, or pancreatic cancer, that has spread or cannot be removed with surgery, and your cancer has a KRAS gene mutation.
You would usually have already received treatment for your cancer, or standard treatment options are no longer suitable or effective.
Study details
This study includes several different treatment groups (called arms), each exploring BBO-11818 either on its own or in combination with other cancer treatments. These treatment arms include:
- BBO-11818 alone
- BBO-11818 with immunotherapy (such as pembrolizumab)
- BBO-11818 with chemotherapy
- BBO-11818 with targeted therapy (such as cetuximab)
- Other combinations with standard treatments used for lung, bowel, or pancreatic cancers.
Across the study, there are two stages:
Stage 1 Dose Escalation: early in the study, smaller groups receive treatment at different dose levels. This helps identify a safe and suitable dose.
Stage 2 Dose Expansion: once a suitable dose is identified, more participants are enrolled into the different treatment arms. This stage looks more closely at how well each treatment approach works.
Conditions
This trial is treating people with locally advanced, unresectable or metastatic non-small cell lung cancer, pancreatic cancer, bowel cancer, or other solid cancers